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ttp://dx.doi.org/10.1016/j.ajpath.2016.12.004Our understanding of the pathophysiological basis of chronic thromboembolic pulmonary hyperten-
sion (CTEPH) will be accelerated by an animal model that replicates the phenotype of human CTEPH.
Sprague-Dawley rats were administered a combination of a single dose each of plastic microspheres
and vascular endothelial growth factor receptor antagonist in polystyrene microspheres (PE) þ
tyrosine kinase inhibitor SU5416 (SU) group. Shams received volume-matched saline; PE and SU
groups received only microspheres or SU5416, respectively. PE þ SU rats exhibited sustained pul-
monary hypertension (62  13 and 53  14 mmHg at 3 and 6 weeks, respectively) with reduction of
the ventriculoarterial coupling in vivo coincident with a large decrement in peak rate of oxygen
consumption during aerobic exercise, respectively. PE þ SU produced right ventricular hypokinesis,
dilation, and hypertrophy observed on echocardiography, and 40% reduction in right ventricular
contractile function in isolated perfused hearts. High-resolution computed tomographic pulmonary
angiography and Ki-67 immunohistochemistry revealed abundant lung neovascularization and cellular
proliferation in PE that was distinctly absent in the PE þ SU group. We present a novel rodent model
to reproduce much of the known phenotype of CTEPH, including the pivotal pathophysiological role of
impaired vascular endothelial growth factoredependent vascular remodeling. This model may reveal
a better pathophysiological understanding of how PE transitions to CTEPH in human treatments.
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Disclosures: None declared.The ﬁeld of pulmonary hypertension research lacks a
reproducible, economically feasible, and pathologically
accurate animal model of chronic thromboembolic pulmo-
nary hypertension (CTEPH). Categorized as group 4 in the
World Health Organization’s classiﬁcation of pulmonary
hypertension (PH), CTEPH uniquely occurs as a direct
result of pulmonary embolism.1,2 Between 0.4% and 9.1%
of patients presenting a single or multiple episodes of acute
pulmonary embolism progress to CTEPH.3e5
CTEPH develops as a consequence of persistent throm-
botic obstruction and scarring of pulmonary arteries, causing
progressive PH and eventual right ventricular (RV) failure.1
One factor heavily associated with CTEPH is multiple
episodes of pulmonary embolism without resolution ofstigative Pathology. Published by Elsevier Incperfusion defects on scintillation lung scanning.6 The path-
ophysiological mechanisms that cause CTEPH are not fully
elucidated, but probably represent the intersection of pre-
disposing patient phenotype and genotype that leads to
resistance to pulmonary intravascular thrombotic clearance,. All rights reserved.
Rat Model of Chronic Pulmonary Embolismtogether with persistent hypercoagulability, platelet activa-
tion,7 pulmonary vascular inﬂammation, vasospasm, in-
ﬂammatory reaction, and vascular cell mitogenesis.8 No
speciﬁc plasmatic biomarker proﬁle has emerged that
predicts or characterizes CTEPH, which hinders the devel-
opment of much-needed prophylactic treatments after ﬁrst
pulmonary embolism diagnosis.9e11 Although CTEPH can
be treated with pulmonary thromboendarterectomy, patient
eligibility and accessibility limit the use of this complicated
surgery, which sometimes fails to cure the disease.12 Treat-
ment with the guanylate cyclase stimulator riociguat may
reverse vasospasm and bring partial symptom relief, but no
medical treatment reverses or even inhibits the progression of
CTEPH.13 Therefore, it is imperative to generate a general-
izable animal model to accelerate the study of CTEPH
pathogenic characteristics and develop new therapeutic
strategies that go beyond treating vasospasm. Many CTEPH
animal models have been attempted with varying success, but
no rodent model has reproduced even the main features of the
human disease, which at minimum requires embolic occlu-
sion followed by progressive PH with RV remodeling.14
Therefore, our goal was to develop a rodent model of
CTEPH that recapitulates the major phenotypic characteris-
tics of the disease but, most important, exhibits a sustained
and progressive PH. We hypothesized that two distinct in-
sults to the pulmonary vascular bed would be required,
comprising the injection of polystyrene microspheres,
together with an inhibitor of the vascular endothelial growth
factor (VEGF) receptor tyrosine kinase (SU5416) to disrupt
VEGF signaling and block the cognate endothelial response
to the pulmonary vascular occlusion.Materials and Methods
All experimental procedures were approved by the Animal
Care and Use Committee of Indiana University School of
Medicine (Indianapolis, IN), and were conducted in accor-
dance with NIH guidelines on animal care and use.15
Induction of Chronic Thromboembolic Pulmonary
Hypertension
Male Sprague-Dawley rats weighing initially 400 to 420 g
were used (39 in total; Harlan Laboratories, Indianapolis,
IN). Animals were assigned into four different groups: i) PE
þ SU group rats received a combination of a single i.v.
(tail vein) dose of polystyrene microspheres (97.000/100 g;
85 mm; Thermo Scientiﬁc, Fremont, CA), dissolved in
0.01% Tween 20,16,17 followed by a single s.c. injection of
the tyrosine kinase inhibitor [SU5416; Tocris Bioscience,
Bristol, UK; 20 mg/kg in dimethyl sulfoxide (DMSO)] to
disrupt post-receptor signaling for the VEGF receptor.18
Injection of the 85-mm polystyrene microspheres was per-
formed to produce vascular occlusion of the fourth-order
branches of the rat pulmonary vasculature, approximatelyThe American Journal of Pathology - ajp.amjpathol.orgcorresponding to segmental branching in humans.19,20
In previous work, we found that autologous clot would not
produce persistent occlusion, even in the Copenhagen rat
treated with the plasmin inhibitor tranexamic acid.21 ii) PE
group received the same dose of polystyrene microspheres
described above and volume-matched DMSO as vehicle.
iii) SU group received vehicle (0.01% Tween 20) and
SU5416 (20mg/kg, s.c. dissolved in DMSO). iv) Sham group
received volume-matched vehicles only (0.001% Tween
20 and DMSO). To assess timing of disease progression,
animals were euthanized at 3 weeks (early stage, n Z 16)
and another subset at 6 weeks (late stage, nZ 22) after PEþ
SU induction or vehicle injection. The dose of SU5416
was chosen on the basis of previous studies with Sugen/
hypoxia-induced pulmonary hypertension model.22,23
Aerobic Capacity Testing
Aerobic capacity was assessed with exercise testing for
maximal rate of oxygen consumption (VO2max), as previ-
ously described,24 using a motorized rodent treadmill
(Columbus Instruments, Columbus, OH). All rats were
familiarized with the treadmill for 8 days before exercise
testing. Familiarization sessions were performed 4 days per
week using gradually increasing treadmill speeds (6 to
24 m/minute) and inclines (0 to 20 degrees) and a mild
electric stimulus at the back of the treadmill belt to promote
learning of running behavior. The duration of each famil-
iarization session was kept to 5 minutes to minimize chronic
training effects. Exercise testing was conducted using
an enclosed treadmill chamber that permits metabolic
measurements via analysis of expired gases (Oxymax;
Columbus Instruments). Gas analyzer calibrations were
conducted before testing using standardized gas
mixtures (Praxair, Indianapolis, IN). For determination of
VO2max, a modiﬁed incremental treadmill protocol was
used25 in 3-minute stages as follows: 10 m/minute at 0 de-
grees, 15 m/minute at 5 degrees, 18 m/minute at 10 degrees,
20 m/minute at 15 degrees, 22 m/minute at 20 degrees, and
25 m/minute at 20 degrees. The test was terminated when
VO2 plateaued despite increasing workload
25 or when the
rat was unable to maintain position on the belt and received
three consecutive electrical stimuli without recovery to the
front of the treadmill. The highest VO2 achieved was
recorded as VO2max (as mL/kg per hour) and is expressed
relative to body weight.
Echocardiography
Rats were lightly anesthetized with 2% isoﬂurane in 100%
O2 via nose cone. Images were obtained in the parasternal
two-dimensional short axis and long axis with a 13- to
24-MHz scan probe (Vevo 2100; Visual Sonics, Toronto,
ON, Canada). Chamber sizes, wall thicknesses, pressures,
and other derived values were assessed in accordance with
published methods.26701
Neto-Neves et alIn Vivo Hemodynamics
Rats were anesthetized (isoﬂurane 2% in 100% O2), intu-
bated, and ventilated via tracheostomy (80 breaths/minute;
inspiratory/expiratory ratio, 1:1; Micro-Ventilator; Kent
Scientiﬁc, Torrington, CT). Systemic pressures were evalu-
ated in the right carotid artery, and instantaneous RV
pressure-volume measurements were obtained with 1.9 F
admittance catheters (Transonic Systems Inc., Ithaca, NY)
positioned in the right ventricle via right thoracotomy and
myocardial puncture. To obtain load-independent measures
of function, the inferior vena cava was transiently occluded
with manual tension held on a silk thread for several seconds.
Heparinized arterial blood was collected and then centrifuged
at 956  g, 15 minutes at 4C and, frozen in liquid nitrogen,
then stored at 80C for biochemical analysis.
Ex Vivo Isolated Perfused Hearts
After euthanasia with ketamine and xylazine overdose,
hearts were excised and perfused via the aorta at a constant
pressure (60 mmHg) in the Langendorff apparatus
with Krebs-Henseleit bicarbonate buffer, as previously
described.16,17 A ﬂuid-ﬁlled balloon connected to a pressure
transducer was inserted into the RV chamber and the Frank-
Starling relationship of RV function (RV-developed pres-
sure and maximum rate of pressure development) was
explored by ﬁlling the balloon with saline to increase the
RV end diastolic pressure from 0 to 40 mmHg with elec-
trical pacing at 350 beats/minute (S44 stimulator; Grass
Instruments, Quincy, MA).
After ex vivo perfusion, the RV was carefully separated
from the left ventricle and septum (LV þ S). After deter-
mination of RV and LV þ S masses, RV/LV þ S ratio was
calculated to determine RV hypertrophy.
High-Resolution CT Pulmonary Vascular Imaging
In euthanized rats obtained from the above listed groups,
heparinized saline (99 parts 0.9%NaCl and 1 part heparin) was
infused through the right jugular vein to ﬂush the pulmonary
circulation free of blood. A barium sulfate contrast medium
(BriteVu; Scarlett Imaging, LLC, Murray, UT) was infused
through the jugular vein catheter with the lungs inﬂated with
20mmHg air, and the tracheawas ligated tomaintain pressure.
Heart and lung blocks were excised and placed on a carbon-
ﬁber bed and scanned with small-animal high-resolution
microecomputed tomography (CT) scanner (Skyscan 1176;
Bruker Biospin Corp., Kontich, Belgium). The micro-CT
images were acquired at 33.63 mm using three continuous bed
positions to cover the entirety of the lungs, where the tube
voltage, current, step-size ﬁlter, and exposure times were 80
kV, 313 mA, 0.9 degrees/step, 0.5 mm Al ﬁlter, and 20 milli-
seconds, respectively. On completion of the micro-CT scans,
images were reconstructed using ﬁltered back projection via
SkyScan NRecon (Kontich, Belgium) software version7021.6.9.4, where a Hamming ﬁlter of 0.25 (a) and a Nyquist
frequency cutoff of 100 Hz yielded isotropic voxels with a
33.63-mm resolution. For analysis, DICOM image volumes
were imported into Analyze 12.0 (AnalyzeDirect, Overland
Park, KS), signal intensity was normalized (ie, 0.0, 1.0), and
tissue segmentation was accomplished via segmented
threshold for background plus soft tissue (ie, 0.0 to 0.1) and
lung vasculature (ie, 0.1 to 1.0). Segmented object maps were
then quantiﬁed for total vascular volumes using Ana-
lyzePro’s ROITool (AnalyzeDirect).
Telemetric Pressure Monitoring
To assess hemodynamics over model development and dur-
ing exercise, we instrumented an additional rat with a dual-
pressure telemetry transmitter (model HD-S21; Data Sciences
International, New Brighton, MN) for simultaneous RV and
aortic pressure measures, as previously described by our
group.24 Brieﬂy, via laparotomy, one catheter was placed into
the abdominal aorta and secured with methacrylate; a second
catheter was inserted into the RV via thoracotomy and
myocardial puncture and secured with a purse-string. The
animal was allowed to recover for 2 weeks before induction
of PE þ SU. In addition to daily resting measures, exercise
pressures were recorded during VO2max testing at baseline,
and at 3 and 6 weeks after PE þ SU induction.
Histology of Heart and Lungs
Formalin-ﬁxed organs were divided into sections (6 mm thick)
and stained with Masson’s trichrome for collagen and
VerhoeffeVan Giesen for collagen in elastic ﬁbers. Lung
cellular proliferation was assessed with Ki-67 immunohisto-
chemistry: slides were blocked for 5 minutes using hydrogen
peroxide to quench endogenous peroxidase, and antieKi-67
rabbit monoclonal antibody (RM-9106-S; Thermo Scientiﬁc,
Fremont, CA) was applied at a 1:200 dilution for 30 minutes.
Envisionþ anti-rabbit kit (Dako Agilent Pathology Solutions,
Santa Clara, CA) was used as secondary antibody. Sections
were developed with diaminobenzidine and counterstained
with hematoxylin. Two observers blinded to study group
examined digitized photomicrographs (Leica Microsystems,
Wetzlar, Germany) to count the number of nuclei staining
Ki-67 positive normalized by the total number of nuclei per
moderate power ﬁeld. The average of the two observers is
reported as percentage of Ki-67epositive cells. Right ven-
tricular ﬁbrosis was assessed on formalin-ﬁxed, parafﬁn-
embedded RV sections as percentage positively stained area
with Masson’s trichrome staining.
Intact Platelet Mitochondrial Oxygen Consumption
Platelets were obtained by serial centrifugation of EDTA-
treated blood (300  g for 15 minutes and 4800  g for 5
minutes subsequently) and were resuspended in platelet-poor
plasma. Approximately 400  106 cells/mL were placed inajp.amjpathol.org - The American Journal of Pathology
Rat Model of Chronic Pulmonary Embolismeach chamber of the Oxygraph (Oxygraph-2k; Oroboros
Instruments, Innsbruck, Austria) at 37C in MIR05 buffer
containing 5 mmol/L glucose and 0.4 mmol/L octanoate.
Oxygen consumption was measured in the absence
(routine or state 4) and presence of oligomycin (leak or
state 3), with the protonophore, carbonyl cyanide
p-(triﬂuoromethoxy) phenylhydrazone (uncoupled) for
electron transport system and extramitochondrial oxygen
consumption was measured by adding rotenone (complex I
inhibitor) and antimycin-A (complex III inhibitor).
Plasma Biomarkers of Endothelial Injury and
Inﬂammation and Arterial Blood Gas Measurements
Tissue inhibitor of metalloproteinases 1, total plasminogen
activator inhibitor-1, caveolin-1, cytokine-induced neutro-
phil chemoattractant-1 (CINC-1/CXCL1, a homolog to
human IL-8), monocyte chemoattractant protein-1, tumor
necrosis factor-a, VEGF, adiponectin, soluble intercellular
adhesion molecule-1, and soluble E-selectin were determined
using a commercially available assay (Milliplex mean arterial
pressure rat vascular injury panels 1 and 2, RV1MAG-26K
and RV1MAG-26K; EMD Millipore Corp., Billerica, MA).
P-selectin (CD62P) concentrations were measured on plasma
samples using a rat sandwich enzyme-linked immunosorbent
assay kit (LS-F5274; LifeSpan Biosciences, Inc., Seattle,Figure 1 In vivo hemodynamics assessment data on early stage (3 weeks) and
right ventricle (RV) of anesthetized rats (AeC), and a conscious, freely moving rat
pressure-sensing catheters (D and F). A: RV systolic pressure (RVSP). B: Index of pul
arterial pressure (MAP). D: RV pressures (systolic and diastolic). E: Systemic pressures
the telemetrically instrumented animal during VO2max testing performed at baseline
after PE þ SU induction. Five minutes of resting collection on a stationary treadm
(arrow) of the incremental treadmill protocol in 3-minute stages. Maximal oxygen
indicated in call-out boxes at each test’s termination point (time to exhaustion) in a
(3 weeks; AeC); n Z 4 to 6 (6 weeks; AeC). *P < 0.05 versus PE þ SU group;
pertension; dSAP, diastolicesystemic arterial pressure; HR, heart rate; RVDP, RV di
The American Journal of Pathology - ajp.amjpathol.orgWA). Arterial blood was examined for lactate, sodium, po-
tassium, hematocrit, and partial pressures of oxygen and
carbon dioxide (PaO2 and PaCO2, respectively) using an i-
STAT device (Abbott Laboratories, Abbott Park, IL). PaO2
and PaCO2 were acquired under spontaneous breathing 21%
O2 (room air) or 100% O2 (delivered by nose cone), and
during mechanical ventilation 100% O2. Alveolar-arterial
oxygenation gradient, A-a O2 Z [(barometric pressure 
water vapor pressure)  FiO2  PaCO2]  PaO2, during
mechanical ventilation of 100% O2.
Statistical Analysis
Data are presented as means  SEM. Means were compared
with a one-way analysis of variance, followed by the
Student-Newman-Keuls multiple comparison post hoc test.
VO2max and PaO2 means were compared with two-way
analysis of variance, followed by Bonferroni post hoc test.
The null hypothesis was rejected at P < 0.05.
Results
Progressive PH Caused by PE þ SU
The combination of a single dose of microspheres and
SU5416 (PE þ SU) produced increases in RV systoliclate stage (6 weeks). Measurements from admittance catheter placed in the
implanted with telemetry system transmitting real-time data from indwelling
monary vascular resistance [RVSP normalized by cardiac output (CO)]. C: Mean
(systolic and diastolic) and heart rate. F: Real-time RVSP tracings recorded in
(light gray line) and at 3 weeks (dark gray line) and 6 weeks (black line)
ill belt (rest), and a 2-minute warm-up period (warm up) preceded the start
uptake (VO2max, in mL/kg/hour), and maximal heart rate (HRmax, in bpm) are
ddition to maximal RVSP. Values are expressed as means  SEM (AeC). nZ 4
yP < 0.05 versus PE group. CTEPH, chronic thromboembolic pulmonary hy-
astolic pressure; sSAP, systolicesystemic arterial pressure.
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Neto-Neves et alpressure (RVSP) (Figure 1A) and pulmonary resistance
(Figure 1B) at 3 and 6 weeks (P < 0.05), without change in
the mean arterial pressure (P > 0.05) (Figure 1C). Neither
the injection of microspheres nor SU5416 alone (PE and SU
groups, respectively) was associated with changes in RVSP,
pulmonary resistance, or mean arterial pressure compared to
the sham group (P > 0.05) (Figure 1, AeC). To better
understand the time-severity course of PH development, we
induced PE þ SU in a rat implanted with telemetric moni-
toring for serial measures of simultaneous RV and aortic
pressures at rest and during maximal exercise testing.
Figure 1D shows that the linear increase in resting RV
systolic pressure occurred between weeks 1 and 3 and pla-
teaued thereafter at an elevated 80 to 100 mmHg.
Throughout this time, the heart rate and aortic pressure
remained stable (Figure 1E). RV pressure increase relative
to increasing exercise workload during VO2max testing
(Figure 1F) was steeper at 3 weeks after PE þ SU induction
(Figure 1F) compared to predisease (Figure 1F), but became704severely blunted at 6 weeks (Figure 1F). In addition to a
failure to generate greater RV pressure with exercise, later
disease was also accompanied by a reduction in resting RV
pressure where, at approximately week 11, the previously
stable but elevated RV values of 80 to 100 mmHg declined
to the mid-60s. The animal then developed gross peripheral
edema and overt respiratory distress, prompting euthanasia.
Necropsy revealed hepatomegaly and ascites. These data
indicate that neither pulmonary vascular occlusion nor
VEGF antagonism alone produce persistent pulmonary
hypertension, but the two insults combined produce pro-
gressive, severe pulmonary hypertension, culminating in
RV failure, a prerequisite to CTEPH.
RV Dysfunction and Hypertrophy Caused by PE þ SU
Echocardiography revealed that PE þ SU rats had increased
RV wall thickness at 3 and 6 weeks (Figure 2A), coincident
with a profound decrease in RV fractional systolicFigure 2 Assessment of cardiac function and
morphology by echocardiography at 3 (white bars)
and 6 (black bars) weeks after chronic thromboem-
bolic pulmonary hypertension (CTEPH) induction. A:
Right ventricular (RV) wall thickness. B: RV fractional
shortening. C: Cardiac output. D: Left ventricular (LV)
wall thickness. E: LV dimension in diastole (LVIDd). F:
RV/LV diameter ratio (as a parameter of enlargement).
G: Representative images from short-axis view echo-
cardiography at early and late stages. Note the strong
RV dysfunction and hypertrophy phenotype in PEþ SU
rats after CTEPH induction. Values are expressed as
means SEM (AeF). nZ 4 per group (3 weeks; AeF);
nZ 4 to 6 per group (6 weeks;AeF). *P< 0.05 versus
PE þ SU group; yP < 0.05 versus PE group; zP < 0.05
for PE versus PE þ SU group.
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Figure 3 Pressure-volume analyses of the right ventricle at 3 (white bars) and 6 (black bars) weeks. End-systolic elastance (Ees; A) and arterial elastance
(Ea; B) increase signiﬁcantly by PE þ SU treatment. C: Because of insufﬁcient enhancement in right ventricular contractility to counterpoise elevated afterload
(Ea), right ventricular-pulmonary arterial coupling (Ees/Ea) reduces in PE þ SU group. Bar graphs represent means  SEM. nZ 4 per group (3 weeks); nZ 4
to 6 per group (6 weeks). *P < 0.05.
Rat Model of Chronic Pulmonary Embolismshortening (Figure 2B) and decreased cardiac output
(Figure 2C). With PE alone, the changes in RV wall
thickness, fractional systolic shortening, and cardiac output
were clearly less severe than with PE þ SU (Figure 2,
AeC). Neither PE nor PE þ SU changed the LV wall
thickness (Figure 2D) or diameter (Figure 2E), but as might
be predicted, PE þ SU increased the mean ratio of the RV/
LV diameter (Figure 2F). The static two-dimensional
echocardiography images displayed in Figure 2G capture
the physiological consequence of this increase in RV
diameter and illustrate that PE þ SU results mimic theTable 1 Ex Vivo RV Intrinsic Contractile Function Parameters Evaluated




RVEDP at 0 mmHg 145  14 151  27
RVEDP at 40 mmHg 307  12* 299  30*
dP/dtmax/RV weight
RVEDP at 0 mmHg 4231  287 5087  926*
RVEDP at 40 mmHg 5895  170* 5822  746*
RV weight (g) 0.29  0.02* 0.30  0.02
LV þ septum weight (g) 1.23  0.04 1.22  0.01
Heart weight (g) 1.53  0.04 1.53  0.02
RV/(LV þ septum) ratio 0.24  0.01* 0.24  0.02
6 Weeks
Developed pressure/RV weight
RVEDP at 0 mmHg 149  12* 127  12*
RVEDP at 40 mmHg 280  11* 258  12*
dP/dtmax/RV weight
RVEDP at 0 mmHg 4699  802* 4093  300*
RVEDP at 40 mmHg 3267  1282* 4836  209*
RV weight (g) 0.30  0.01* 0.34  0.01
LV þ septum weight (g) 1.18  0.04 1.26  0.04
Heart weight (g) 1.49  0.05* 1.61  0.06
RV/(LV þ septum) ratio 0.25  0.01* 0.27  0.02
RV-developed pressure and the maximum rate of increase in RV pressure duri
RVweight (mmHg/g) and dP/dtmax/RVweight (mmHg/s/g) were acquired at differe
used as a marker of RV hypertrophy. Values are means  SEM. n Z 4 to 6 per g
*P < 0.05 versus PE þ SU group.
yP < 0.05 for PE versus PE þ SU group.
CTEPH, chronic thromboembolic pulmonary hypertension; dP/dtmax, RV-develope
PE, polystyrene microsphere; RV, right ventricular; RVEDP, RV end diastolic press
The American Journal of Pathology - ajp.amjpathol.orgechocardiographic pattern seen in humans with CTEPH
(namely, that the RV displaces the septum to the left and
compresses the LV). Rats with PE þ SU also demonstrated
a signiﬁcant reduction in the pulmonary artery acceleration
time/RV ejection time and 100% of PE þ SU rats had the
midsystolic notch, as observed in representative images of
pulmonary artery velocities on Doppler echocardiogram
(Supplemental Figure S1, A and B), whereas no rat in any
other group had the midsystolic notch.
Figure 3 shows results of load-independent measurements
of right ventricular function. End-systolic elastanceby Isolated Perfused Hearts and Cardiac Mass (Heart, RV, and LV þ
PE PE þ SU Comparison
95  41 51  9 P > 0.05
214  37 128  12y P < 0.05
3101  1313 1524  260 P < 0.05
3493  1320 2282  149 P < 0.05
* 0.34  0.01 0.62  0.04y P < 0.05
1.27  0.04 1.12  0.08 P > 0.05
1.61  0.04 1.75  0.11 P > 0.05
* 0.27  0.01 0.55  0.03y P < 0.05
93  46 57  3 P < 0.05
227  52 126  4y P < 0.05
2593  1160 1797  135 P < 0.05
3267  1282 2269  119 P < 0.05
* 0.33  0.02 0.71  0.03y P < 0.05
1.18  0.04 1.17  0.07 P > 0.05
* 1.52  0.05 1.88  0.09y P < 0.05
* 0.28  0.01 0.65  0.06y P < 0.05
ng systole (dP/dtmax) were corrected for RV weights. Developed pressure/
nt RV end diastolic pressures (0 and 40 mmHg). RV/LV þ septum ratio was
roup.
d pressure and maximum rate of pressure development; LV, left ventricular;
ure; SU, tyrosine kinase inhibitor SU5416.
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Neto-Neves et al(P < 0.05) (Figure 3A) and arterial elastance (P < 0.05)
(Figure 3B) were elevated in PE þ SU group, resulting in
reduction of the ventriculoarterial coupling (end-systolic
elastance/arterial elastance, P < 0.05) (Figure 3C).
No changes in LV function were found.
We then measured RV intrinsic contractile function in
isolated perfused hearts. Hearts isolated from PE þ SU rats
at 3 and 6 weeks had signiﬁcantly worsened RV-developed
pressure and maximum rate of pressure development
normalized by RV mass, compared with sham and SU
groups (Table 1). After perfusions, the heart and each
ventricle were weighed to assess the Fulton index, which
revealed a signiﬁcant increase in RV mass (greater than
twofold, P < 0.05), but no change in LV þ Septum mass
leading to an increase in the RV/LV þ S ratio (RV massFigure 4 Maximal aerobic capacity expressed as VO2max (A and B), total exercis
after PE þ SU induction. Values are means  SEM (AeF). *P < 0.05 for sham ve
versus PE þ SU group.
706normalized by LV þ S). Thus, PE þ SU produced RV
contractile dysfunction, both in vivo and ex vivo, coincident
with marked RV hypertrophy.
PE þ SU Worsens Exercise Capacity of Rats and Causes
Hypoxemia
PE þ SU produced a 40% and 32% reduction in VO2max at
3 and 6 weeks compared to sham rats at the same time
points (P < 0.05) (Figure 4, A and B). In parallel, we
observed decrements in exercise time, whereas the respi-
ratory exchange ratio increased above unity, suggesting
dominant lactate oxidation (P < 0.05) (Figure 4, CeF). PE
alone produced 6% reduction in mean VO2max at 3 weeks
and 11% at 6 weeks (P > 0.05) (Figure 4, A and B).e time (C and D), and respiratory exchange ratio (E and F) at 3 and 6 weeks
rsus PE þ SU group; yP < 0.05 for sham versus PE group; zP < 0.05 for PE
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Figure 5 A: Partial pressure of arterial oxygen (PaO2) was assessed
during spontaneous breathing of 21% O2 (room air), spontaneous breath-
ing of 100% O2, and mechanical ventilation of 100% O2 after 6 weeks of PE
þ SU induction. B: Alveolar-arterial oxygenation gradient (A-a O2) was
calculated during mechanical ventilation of 100% O2. C: Simultaneously,
arterial blood samples were used to measure lactate concentrations in
sham, PE, and PE þ SU rats at 6 weeks. *P < 0.05 versus PE þ SU group;
yP < 0.05 for sham versus PE group.
Rat Model of Chronic Pulmonary EmbolismArterial blood samples demonstrated mild reduction in the
PaO2 in rats of PE and PE þ DMSO groups compared to
sham rats during spontaneous breathing of 100% O2
(P < 0.05) (Figure 5A). However, during mechanical
ventilation, 100% O2 only PE group showed lower PaO2
compared to sham rats (P < 0.05) (Figure 5A). Increased
alveolar-arterial oxygenation gradient (A-a O2) was found
elevated in PE and PE þ SU groups compared to sham rats
during mechanical ventilation of 100% O2 (P < 0.05)
(Figure 5B). Although A-a O2 gradient tended to be higher
in PE group rather than PE þ SU group, it was not
signiﬁcantly different at the a Z 0.05 level (Figure 5B).The American Journal of Pathology - ajp.amjpathol.orgIn addition, arterial lactate concentrations were increased
in rats with PE þ SU (8.9  2.4 mmol/L) versus sham rats
(2.5  0.4 mmol/L) at 6 weeks (P < 0.05) (Figure 5C).
Although sodium plasma concentrations were similar be-
tween all groups (P > 0.05) (Supplemental Figure S2A),
PE þ SU was associated with mild increase in serum
potassium concentrations and lower hematocrit compared
to sham and PE groups (P < 0.05) (Supplemental
Figure S2, B and C).Association of a CTEPH-Like State with Circulating
Markers of Endothelial Injury, Inﬂammation, and
Platelet Activation
Taken together, the hemodynamic, echocardiographic,
morphological, intrinsic contractility, and histological data
suggest that PE þ SU in rats produces many of the same
consequences of CTEPH in humans. The next question
was to determine whether PE þ SU produces changes in
plasma biomarkers of hypoﬁbrinolysisdreduced collagen
proteolysis and platelet activation, suggestive of a pheno-
type of clot persistence, RV and vascular hypertrophy, and
small-vessel occlusion, respectively. Indeed, the plasma
concentrations of tissue inhibitor of metalloproteinases 1,
total plasminogen activator inhibitor-1, and P-selectin were
elevated in the PE þ SU group compared to the others
groups (Figure 6, AeC). Intact platelets isolated from PE þ
SU rats also had signiﬁcantly elevated oxygen consumption
in two states of respiration, including unstimulated (routine,
55  8 versus 31  2 pmol  s1/106 cells) and uncoupled
(electron transport system, 86  13 versus 44  4 pmol 
s1/106 cells) conditions with greater wasted oxygen use
(leak, 10  1 versus 5  1 pmol  s1/106 cells), compared
to sham rats (P < 0.05) (Figure 6D). These results indicate
marked elevated rates of mitochondrial oxidative phos-
phorylation with mild uncoupling in platelets of PE þ SU
rats. No extramitochondrial oxygen consumption was
detected. Additional biomarkers at 5 days, 3 weeks, and 6
weeks after CTEPH are shown in Supplemental Figure S2
(SU group was not included because no difference was
found between sham group). PE þ SU produced elevations
on caveolin-1, CINC-1, and tumor necrosis factor-a, and
reductions on adiponectin at 5 days after CTEPH induction
in PE þ SU group (P < 0.05) (Supplemental Figure S3, A,
B, D, and F). In addition, tumor necrosis factor-a and adi-
ponectin decreased in PE group at 5 days (P < 0.05)
(Supplemental Figure S3, D and F). At 3 weeks, CINC-1,
VEGF, soluble E-selectin, and soluble intercellular adhe-
sion molecule-1 increased in plasma of PE þ SU rats,
whereas CINC-1 decreased in PE group (P < 0.05)
(Supplemental Figure S3, B, E, G and H). At 6 weeks, only
monocyte chemoattractant protein-1 and VEGF were
elevated on PE þ SU group, and CINC-1 decreased in PE
and PE þ SU groups (P < 0.05) (Supplemental Figure S3,
B, C, and E).707
Figure 6 Plasma concentrations of tissue in-
hibitor of metalloproteinases 1 (TIMP-1; A), total
plasminogen activator inhibitor-1 (tPAI-1; B), and
P-selectin (C) in sham, SU, PE, and PEþ SU groups at
3 weeks and 6 weeks. D: Platelet mitochondrial
respiration in sham, PE, and PE þ SU groups at 6
weeks. Values are means  SEM. n Z 4 (AeC, 3
weeks); nZ 4 to 6 (AeC, 6 weeks); nZ 8 (D, sham
group); n Z 5 (D, PE group); n Z 7 (D, PE þ SU
group). *P < 0.05 for PE þ SU group versus other
groups; yP < 0.05 for sham versus PE þ SU group;
zP < 0.05 for PE versus PEþ SU group.
Neto-Neves et alHigh-Resolution CT Angiography Demonstrates
Pulmonary Vascular Rarefaction with PE þ SU
Figure 7, AeC, shows three-dimensional images from
micro-CT scan that demonstrate robust increase in the
number and distension of small (greater than the fourth
order branch) pulmonary arteries and arterioles in PE group
compared to sham group (Figure 7, A and B). However,
Figure 7C shows that lungs from rats treated 6 weeks before
with PE þ SU demonstrate vascular pruning, and frank loss
of peripheral vasculature beyond fourth-order branching.
The pulmonary vascular volume was found to be reduced in
PE þ SU group (789  114 mm3) compared to sham group
(1369  175 mm3, P < 0.05) (Figure 7D). However, in PEFigure 7 Lung compute
pulmonary hypertension. Rep
and magniﬁcations (left and r
with microspheres only (B),
SU5416 (20mg/kg; C). D: Qua
groups. nZ 4 per group (D).
708group, pulmonary vascular volume tended to be elevated
(2312  816 mm3) (Figure 7D).
Increased RV Fibrosis and Lung Vascular Hyperplasia in
Parallel with Impaired Lung Growth
PE þ SU rats had marked decrease in cellular proliferation,
expressed as Ki-67e positive cells in percentage of total
cells nuclei per ﬁeld, compared with rats in the sham and PE
groups (P < 0.05) (Figure 8, A and B). Lung sections
stained with VerhoeffeVan Giesen (Figure 8C) demon-
strated marked medial hypertrophy in small arterioles,
occasional intimal proliferation with obliteration of the
lumen, but without plexiform lesions. In addition,d tomography imaging at 6 weeks after chronic thromboembolic
resentative three-dimensional microecomputed tomographic images
ight sides) of sham rats injected with vehicle only (A), PE rats injected
and PE þ SU rats injected with a combination of microspheres and
ntiﬁcation of the pulmonary vascular volume in sham, PE, and PEþ SU
*P < 0.05 for sham versus PE þ SU group.
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Figure 8 A: Cellular proliferation was assessed by quantiﬁcation of the Ki-67epositive cells (expressed as Ki-67epositive cells in percentage of total cells
nuclei per ﬁeld) in the sham, PE, and PE þ SU rats. B: Representative images of immunohistochemistry for Ki-67 stain (positive cells indicated by arrows) on
rat lung sections from animals in the sham, PE, and PE þ SU groups at 6 weeks. C: Verhoeffevan Gieson staining reveals medial hypertrophy and lumen
obliteration in small pulmonary arterioles in PE þ SU rats. Histological sections of Masson’s trichrome staining [left ventricular (LV; (D) and right ventricular
(RV; E)] on sham, PE, PE þ SU, and SU groups at 6 weeks after chronic thromboembolic pulmonary hypertension. Masson’s trichrome stain showing RV ﬁbrosis
(blue color indicates collagen accumulation) in PE group but more extensive in the PE þ SU group. No LV ﬁbrosis is observed. nZ 6 per group (A). *P < 0.05
for sham and PE versus PE þ SU group. Scale bars: 50 mm (B, D, and E); 200 mm (C). Original magniﬁcation, 200 (BeE).
Rat Model of Chronic Pulmonary Embolismtrichrome-stained sections (P < 0.05) (Figure 8E and
Supplemental Figure S4) demonstrate moderate RV-speciﬁc
ﬁbrosis with PE alone, and showed more severe RV-speciﬁc
ﬁbrosis with PE þ SU. No signiﬁcant increase in ﬁbrosis
was observed in the LV with any group or in the RV with
SU alone (Figure 8D).
Discussion
In a novel model, rats with pulmonary vascular occlusion
only with impervious microspheres failed to manifest
CTEPH-like states, but when subjected to inhibition of the
endothelial proliferative response mediated by VEGF with
SU5416 in PE þ SU group, the animals show phenotypic
proﬁles suggestive of CTEPH. Without variability, 100% of
rats treated with PE þ SU manifested progressive elevation
of pulmonary pressure and resistance, concomitant with RV
dysfunction, enlargement and hypertrophy, exerciseThe American Journal of Pathology - ajp.amjpathol.orgintolerance,27 platelet activation,7 and pulmonary vascular
atrophy.28 Only approximately 10% of rats with PE þ
DMSO developed PH, and in data not shown, we repeated
weekly microsphere embolization (up to ﬁve times over 6
weeks but without SU5416) in dozens of rats and were
unable to produce consistent PH.16,17 Similarly, repeated
injections of ﬁbrinogen/collagen-covered polystyrene mi-
crospheres together with thrombin produced minor eleva-
tions of the RVSP (<33 mmHg) in a rat model of CTEPH.29
These ﬁndings reafﬁrm the requirement of a combined
insult of pulmonary vascular occlusion and inhibition of
endothelial proliferation (accomplished herein via blocking
tyrosine kinase, required for VEGF signaling) to produce
persistent PH after PE.30 We observe that >90% of rats with
PE but without VEGF antagonism have systolic pulmonary
arterial pressures <35 mmHg, and together with obviously
increased vascularity on high-resolution CT pulmonary
angiography and lung cellular proliferation on Ki-67709
Neto-Neves et alstaining. Taken together, these ﬁndings increased pulmo-
nary vascular cross-sectional area by either pulmonary
arterial dilation, or more likely, growing new vessels to
increase the net pulmonary vascular cross-sectional area.
With PE alone, the lung cellular proliferation estimated with
Ki-67 staining did not differ from the sham group, whereas
with PE þ SU, the lung cellular proliferation decreased,
coincident with marked vascular pruning on high-resolution
CT angiography (Figures 7 and 8). Loss of peripheral
vascularity is considered a radiological hallmark of CTEPH
in humans.31e33 However, on histological examination,
humans with CTEPH demonstrate a range of vascular
morphometric abnormalities, from complete loss of vessels
to intimal and muscular hyperplasia, and occasional plexi-
form lesion formation.31,34,35 Indirect evidence has sug-
gested that pulmonary arteriolar/capillary remodeling and
vasospasm contribute to persistent PH after PE, given that
the increased pulmonary vascular resistance correlates
poorly with the degree of angiographic pulmonary vascular
bed obstruction in humans (with pressures most often
disproportionately high).36,37 Kasahara et al38 found that
SU5416 alone can cause emphysema by endothelial cell
apoptosis. However, in that work, the animals were injected
s.c. three times per week for 3 weeks with 20 mg/kg
SU5416. In our model, we only used one injection of 20
mg/kg SU5416. Although we did not measure emphysema,
no enlarged airspaces were found in rats injected with
SU5416, as was seen by Kasahara et al.38 In addition, we
believe that vasoconstriction will not play an important role
on our imaging because the CT scans were performed post-
mortem. Therefore, the pulmonary vascular rarefaction may
be the most important effect for intravascular barium
exclusion in lungs of rats in PE þ SU group.
If future work conﬁrms that healthy rats with PE alone
forestall PH by VEGF-dependent pulmonary vascular
expansion, our model may help advance a treatment strategy
to increase lung angiogenesis to prevent or possibly reverse
CTEPH. Precedent literature has described cytotherapy with
mesenchymal stem cells to partially reverse the phenotype
of pulmonary arterial hypertension produced by mono-
crotaline.39 This would be especially important in the so-
called type 4 CTEPH, caused by widespread distal
emboli, rendering it less amenable to surgical treatment or
pulmonary balloon angioplasty of proximal obstruction.40,41
The lack of a markedly widened A-a O2 tension difference
gradient in animals with PE alone argues against a large
physiological shunt from bronchiolar dilation or collateral
vessel formation, which has been suggested to occur in
CTEPH.42,43 Our A-a O2 tension difference gradients
(35  11 mmHg) are consistent with those found by
McCabe et al44 in 15 humans with CTEPH (46  12
mmHg). Therefore, the vascular compensation in rats with
PE alone appears to be either salutary or at least not harmful,
in terms of pulmonary ventilation perfusion and gas ex-
change. The age of the rats may affect this vascular
expansion as a compensatory response. Herein, we studied710male rats, all <6 months old. Given that a Sprague-Dawley
rat’s mean lifespan is approximately 3 years in captivity, it
must be considered that our model represents the juvenile
response to acute PE. Whether aged rats can compensate
equally well remains unknown.
We found an elevation of biomarkers of hypoﬁbrinolysis
and reduced collagen proteolysis and platelet activation (PAI-
1, tissue inhibitor of metalloproteinases 1, and p-Selectin,
with marked increase in intact platelet oxygen consumption)
(Figure 6) in the CETPH group (PE þ SU). Increased levels
of PAI-1, in the thrombi, and highly activated platelets (P-
selectinepositive cells) have been reported in CTEPH pa-
tients.7,45 In addition, PAI-1 and tissue inhibitor of metal-
loproteinases 1 have been reported to inhibit angiogenesis,
through VEGF pathway disruption46 and protease inhibi-
tion,47 respectively. Furthermore, low expression of proan-
giogenic factors in white CTEPH thrombi has been proposed
to impair angiogenesis-induced thrombi resolution.48
Limitations include use of polystyrene microspheres
instead of native thrombi21 and male juvenile rats. Only the
animal instrumented with implantable telemetry was studied
out to the point of frank RV failure, incident at 10 weeks.
The exercise hemodynamics recorded for this animal
reﬂected a failing RV in later disease, where increase in
pulmonary pressure relative to workload became distinctly
plateaued, similar to a pattern that has been reported to be
prognostic for patients with pulmonary arterial hypertension
in RV exercise catheterization studies.49 We do not know if
this time frame to RV failure will be reproducible, but the
mean lactate values of 9 mmol/L at 6 weeks suggests
animals had circulatory insufﬁciency.
In conclusion, in the present model, we found that the
interaction of pulmonary arterial mechanical obstruction and
VEGF receptor inhibition recapitulate main features of
clinical CTEPH, consistent with the dual pulmonary injury
concept. This novel model provides experimental evidence
for the relation between progressive pulmonary pressure
elevation and deﬁcient lung vascularization in the CTEPH
pathophysiology and opens the way to better understanding
of the role of pulmonary vascular expansion as a therapeutic
target to prevent CTEPH in the setting of unresolved PE.
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